Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN

Phase 2

Active, not recruiting

• Conditions: HNSCC
• Interventions: Drug: Durvalumab

• Registration Number: NCT03726775
• Lead Sponsor: Groupe Oncologie Radiotherapie Tete et Cou

Brief Summary

This study evaluate the regional (neck) nodal control of durvalumab in combination with RT restricted to the primary tumor and the immediately adjacent nodal level (i.e. without prophylactic neck irradiation) in N0 patients with SCCHN.

Detailed Description

There is a strong rationale for testing this new paradigm of RT for SCCHN without prophylactic neck irradiation, being replaced by immune stimulation via the combination of RT and Programmed Death-1 (PD-L1) inhibition with durvalumab, due to:

* The unmet medical need for new treatments, better tolerated and " as " or " more " effective than the current Standard Of Care (SOC)

* The need to decrease radiation-induced toxicity, especially in fragile patients

* The added toxicity due to elective nodal irradiation

* The strong rationale to combine RT and PD-L1 inhibition

* The potential immune suppressive effect of large field prophylactic neck irradiation

It is hypothesized this innovative concept to be safe in the context of this study for the following reasons:

* The rate of relapse in the neck is expected to be low in Magnetic Resonnance Imaging (MRI) \& PET-CT N0 neck

* A non-irradiated neck can be easily monitored, clinically and by imaging

* Most of the potential relapses in the neck are expected to be salvaged by surgery and/or RT

* The preventive irradiation of N0 regions is not anymore performed for others lymphophilic cancers (lymphoma, Non-Small Cell Lung Cancer (NSCLC)).

The combination of durvalumab with RT restricted to the primary tumor site and immediate adjacent nodal area will achieve a similarly regional (nodal) control rate than standard RT including large prophylactic neck irradiation (regional recurrence \< 10 %.

This study will include patients with early (T1-T2 N0) or locally advanced SCCHN (T3-4 N0), histologically proven who had not received previous treatment for this setting. The study is designed with the primary objective of demonstrating that RT without large prophylactic irradiation in combination with durvalumab is effective in terms of regional control. All patients will be followed until death or at least 36 months.

Study Timeline

• Study First Submitted: 2018-10-25
• Study First Submitted QC: 2018-10-30
• Study First Posted: 2018-10-31
• Study Start: 2019-07-17
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-06
• Last Update Posted: 2025-05-07
• Primary Completion: 2026-07
• Study Completion: 2026-08

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 61

Inclusion Criteria

1. Age > 18 years with no upper limit

2. Performance Status ECOG 0-2

3. Squamous cell carcinoma, previously untreated

4. T1-T4 with clinical status N0-N1 or N2a-N2b non palpable, with only homolateral lymph node in radiological examinations.

5. Patient with at least one of these fragility criteria :

   o Status ECOG 1 with multiple comorbidities, at least 2 pathologies with grade ≥ 2 (renal and/or cardiac and/or vascular and/or hepatic, and/or,neurologic, and/or pulmonary)

   o Status ECOG = 2

   o Age ≥ 70 , judged unfit with oncogeratric evaluation by EGE (ELAN Geriatric Evaluation) test or unable to receive cisplatine or Carboplatine- 5FU (at least one criteria listed below*)

   * Criteria for determining if a patient is unfit for receiving cisplatine or carbo-5FU :

   • Calculated creatinine clearance ≤ 60 mL/min as determined by the modified. method of Cockcroft and Gault or glomerular filtration rate ≤ 60 mL/min/1.73m² (CKD-EPI method recommended)

   • Haemoglobin < 10 g/dL, aspartate (AST) and alanine transaminase (ALT) more than 2 times the upper limit of the normal range (ULN), serum albumin ≤35 g/L, Absolute neutrophil count ≤ 1 500/μL, platelets ≤ 100 000/μL or total bilirubin ≥ 1.5 mg/dL

   • Cardiac function not compatible with hyperhydration or significant heart disease
   • Weight loss > 15% in 2 months

6. Oral cavity, oropharynx, hypopharynx or larynx

7. Availability of pre-treatment tumor tissue sample (for PD-L1 expression, TILs and immune landscape)

8. Documentation of p16 disease (HPV status for oropharyngeal tumor)

9. Recording of alcohol consumption and smoking history

10. Glomerular filtration rate (GFR) >40 mL/min/1.73m2 (CKD-EPI method recommended) or Calculated creatinine clearance CL>40 mL/min by the Cockcroft-Gault formula

11. Patient willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations during the follow up period

12. Patient able to understand French and complete the quality of life questionnaires or who can be helped by a support person if necessary.

13. Must have a life expectancy of at least 12 weeks

14. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

1. Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and folliclestimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).

2. Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).

15. Written informed consent obtained prior to performing any protocol-related procedures, including screening evaluations

Exclusion Criteria

1. Nasopharyngeal, paranasal sinuses, nasal cavity tumors or thyroid cancers

2. Metastatic disease

3. Active CNS disease

4. Any prior or current treatment for invasive head and neck cancer

5. Any unresolved toxicity NCI CTCAE v5.0 Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.

   1. Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis
   2. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the investigator

6. Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable

7. History of leptomeningeal carcinomatosis

8. Body weight ≤ 30 kg and/or weight loss of ≥ 15% during the last 4 weeks (except if renutrition with a feeding tube is planned before the onset of treatment or is ongoing)

9. Concurrent treatment with any other systemic anti-cancer therapy that is not specified in the protocol

10. Concomitant treatment with any drug on the prohibited medication list such as live vaccines within 30 days prior to the first dose of IP

11. Known allergy or hypersensitivity reaction to study drug or any of the study drug excipients

12. Prior organ transplantation including allogenic stem-cell transplantation

13. Other severe acute or chronic medical conditions including pneumonitis, pulmonary fibrosis

14. Active autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc])

15. Uncontrolled intercurrent illness, including but not limited to, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent

16. History of another primary malignancy except for:

    1. Malignancy treated with curative intent and with no known active disease ≥ 5 years
    2. Adequately treated non-melanoma skin cancer
    3. Adequately treated carcinoma in situ without evidence of disease

17. History of active primary immunodeficiency

18. Ongoing or active infection including tuberculosis, hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA

19. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:

    1. Intranasal, inhaled, topical steroids, or local steroid injections
    2. Systemic corticosteroids < 10 mg/day of prednisone or its equivalent
    3. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)

20. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy

21. Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment

22. Individual deprived of liberty, or under any kind of guardianship

23. Inclusion in another study research on drug or medical device

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
RT-durvalumab	Durvalumab	durvalumab at fixed dose of 1120 mg on Day1 of RT and every 3 weeks during the RT. Durvalumab with be continued at a fixed dose of 1500 mg every 4 weeks during 6 months following RT.

Primary Outcome Measures

Name	Time	Method
Regional (neck) nodal control rate	1 year	Cervical Node Control in the non-irradiated N0 neck

Secondary Outcome Measures

Name	Time	Method
Survival analyses	3, 7, 11, 15, 19, 23, 27, 31, and 36 months post RT	Estimation of the survival rates and the 95% confidence intervals (95% CI)
Quality of life QLQC30	baseline, 3-month, 12-month and 24-month post RT	To evaluate the effectiveness of support
Recurrence and control rates analysis	3, 6, 12, 18, 24 and 36 months	Estimation of local, regional, locoregional control
Quality of life QLQ-H&N35	baseline, 3-month, 12-month and 24-month post RT	To evaluate the effectiveness of support
Objective Response Rate	3, 12, 24 et 36 months post RT	complete or partial response according to RECIST 1.1 criteria

Trial Locations

Locations (2)

Institut Sainte Catherine; 🇫🇷 Avignon, France

Centre Eugene Marquis; 🇫🇷 Rennes, France